Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 20/20 | 0.72 |
| ▸ | CYBB | P04839 | 6/20 | 0.72 |
| ▸ | NOX1 | Q9Y5S8 | 6/20 | 0.72 |
| ▸ | NOX5 | Q96PH1 | 5/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29523003 | 1.00 | NOX4 (0.72) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL16612593 | 0.86 | NOX4 (0.77) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL16612522 | 0.85 | NOX4 (0.75) | NOX4CYBBNOX1NOX5CYP3A4 | |
| Setanaxib SCHEMBL1302603 | 0.84 | NOX4 (1.00) | NOX4CYBBNOX1NOX5CYP3A4 | |
| Setanaxib SCHEMBL29375704 | 0.84 | NOX4 (1.00) | NOX4CYBBNOX1NOX5CYP3A4 | |
| Setanaxib SCHEMBL29362127 | 0.84 | NOX4 (1.00) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL16612222 | 0.84 | NOX4 (0.74) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL18942675 | 0.83 | NOX4 (0.61) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL1302943 | 0.82 | NOX4 (0.72) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL16612805 | 0.80 | NOX4 (0.72) | NOX4CYBBNOX1NOX5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-03-04 | — | — | US | claimed |
| CN-111971284-A | COMBINATION MODES OF NUCLEOSIDE AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELLIS-SPECIFIC ANTIVIRAL AGENTS | 埃默里大学 | 2020-11-20 | — | — | CN | claimed |
| EP-3732180-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | Emory University (US) | 2020-11-04 | — | — | EP | claimed |
| EP-2776027-B1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | GENKYOTEX SUISSE SA (CH) | 2017-06-07 | — | — | EP | claimed |
| WO-2015049655-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF PDE5 INHIBITOR-POORLY RESPONSIVE ERECTILE DYSFUNCTION | GENKYOTEX SA (CH) | 2015-04-09 | — | — | WO | claimed |
| EP-2857399-A1 | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction | GenKyoTex SA (CH) | 2015-04-08 | — | — | EP | claimed |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2014-10-30 | — | — | US | claimed |
| EP-2591782-A1 | Nadph oxidase 4 inhibitors and use thereof | Johann Wolfgang Goethe-Universität (DE) | 2013-05-15 | — | — | EP | claimed |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4319763-A2 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319762-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319764-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022217155-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2015049655-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF PDE5 INHIBITOR-POORLY RESPONSIVE ERECTILE DYSFUNCTION | GENKYOTEX SA (CH) | 2015-04-09 | — | — | WO | disclosed |
| EP-2857399-A1 | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction | GenKyoTex SA (CH) | 2015-04-08 | — | — | EP | disclosed |
| EP-2857399-A1 | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction | GenKyoTex SA (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2014-10-30 | — | — | US | disclosed |
| EP-2591782-A1 | Nadph oxidase 4 inhibitors and use thereof | Johann Wolfgang Goethe-Universität (DE) | 2013-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | MTAP, NSUN3, METTL3 | NOX4 2517/4885CYBB 4042/4885NOX1 2070/4885 |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | NOX1, NOX3, NOX4 | NOX4 3/4885CYBB 6/4885NOX1 1/4885 |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | NOX4 2891/4885CYBB 3145/4885NOX1 1125/4885 |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | NOX4, NOX1, NOX5 | NOX4 1/4885CYBB 6/4885NOX1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.